Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
09:25am, Friday, 22'nd Aug 2025
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has autho
Moderna to Present at Upcoming Conferences in September 2025
07:00am, Thursday, 21'st Aug 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global He
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
09:30am, Sunday, 17'th Aug 2025
Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies.
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
01:55pm, Monday, 11'th Aug 2025
View Preview
The 3 Things That Matter for Moderna Now
05:22am, Monday, 11'th Aug 2025
Since hitting their peak in late 2021, Moderna's (MRNA -1.69%) shares are down by more than 90%. The biotech company gained recognition by developing one of the leading coronavirus vaccines on the mar
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
02:19pm, Wednesday, 06'th Aug 2025
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop fundi
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
09:33am, Monday, 04'th Aug 2025
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting in
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
07:01pm, Friday, 01'st Aug 2025
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street e
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
04:51pm, Friday, 01'st Aug 2025
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
02:26pm, Friday, 01'st Aug 2025
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
11:56am, Friday, 01'st Aug 2025
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Rela
Moderna slashes full-year sales outlook, reduces headcount
11:23am, Friday, 01'st Aug 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
11:10am, Friday, 01'st Aug 2025
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna cuts 2025 revenue to $2.2B after UK booster delay
10:11am, Friday, 01'st Aug 2025
Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
09:11am, Friday, 01'st Aug 2025
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.
